Systemic therapy for renal cell carcinoma

Journal of Urology

Volumn 163, Issue 2, 2000, Pages 408-417

  Motzer, Robert J ^a   Russo, Paul ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Carcinoma; Drug therapy; Interferons; Interleukins; Renal cell

Indexed keywords

ACRIVASTINE; CIMETIDINE; CYCLOSPORIN A; DIPYRIDAMOLE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IRINOTECAN; LEVAMISOLE; LONIDAMINE; MAFOSFAMIDE; MEDROXYPROGESTERONE ACETATE; MERBARONE; PACLITAXEL; QUINIDINE; ROQUINIMEX; SURAMIN; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG; VALSPODAR; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DATA ANALYSIS; HUMAN; KIDNEY CARCINOMA; MEDICAL INFORMATION; MEDICAL RECORD; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0033978220     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67889-5     Document Type: Review

References (176)

1. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma. N Engl J Med, 335: 865, 1996
2. Motzer, R. J. and Vogelzang, N. J.: Chemotherapy for renal cell carcinoma. In: Principles and Practice of Genitourinary Oncology. Edited by D. Raghaven, H. I. Scher, S. A. Leibel et al. Philadelphia: Lippincott-Raven, chapt. 85, pp. 885-896, 1997
3. Yagoda, A.: Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988. Prog Clin Biol Res, 350: 227, 1990
4. Yagoda, A., Petrylak, D. and Thompson, S.: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am, 20: 303, 1993
5. Yagoda, A., Abi-Rached, B. and Petrylak, D.: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol, 22: 42, 1995
6. Wirth, M. P.: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am, 20: 283, 1993
7. Motzer, R. J., Russo, P., Nanus, D. M. et al: Renal cell carcinoma. Current Problems in Cancer, 21: 189, 1997
8. Fisher, R. I., Rosenberg, S. A., Sznol, M. et al: High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am, suppl., 3: S70, 1997
9. Miller, A. B., Hoogstraten, B., Staquet, M. et al: Reporting results of cancer treatment. Cancer, 47: 207, 1981
10. Vogelzang, N. J., Priest, E. R. and Borden, L.: Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol, 148: 1247, 1992
11. Oliver, R. T., Nethersell, A. B. and Bottomley, J. M.: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol, 63: 128, 1989
12. Gleave, M. E., Elhilali, M., Fradet, Y. et al: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med, 338: 1265, 1998
13. Rosenberg, S. A., Lotze, M. T., Yang, J. C. et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst, 85: 622, 1993
14. Abrams, J. S., Rayner, A. A., Wiernik, P. H. et al: High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst, 82: 1202, 1990
15. Negrier, S., Escudier, B., Lasset, C. et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272, 1998
16. Thiesse, P., Ollivier, L., Di Stefano-Louineau, D. et al: Response accuracy in oncology trials: reasons for interobserver variability. Groupe Francis d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol, 15: 3507, 1997
17. Stadler, W. M., Kuzel, T., Dumas, M. et al: Multi-center phase II trial of interleukin-2, interferon-alpha, and 13 cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol, 16: 1820, 1998
18. McLean, J., Loehrer, P., Picus, J. et al: A phase II study of altretramine for the treatment of metastatic renal cell carcinoma: a Hoosier Oncology trial. Proc Am Soc Clin Oncol, 13: 244, 1994
19. Higano, C. S., Goodman, P., Craig, J. B. et al: Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study. Invest New Drugs, 9: 361, 1991
20. Witte, R. S., Hsieh, P., Elson, P. et al: A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell carcinoma. Invest New Drugs, 14: 409, 1996
21. Trump, D. L. and Elson, P.: Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs, 8: 201, 1990
22. Berg, W. J., Schwartz, L. H., Amsterdam, A. et al: A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs, 15: 353, 1997
23. Chauvergne, J., Kerbrat, P., Adenis, A. et al: Phase II study of cystemustine in advanced renal cancer. Eur J Cancer, 31A: 130, 1995
24. Herrmann, R., Manegold, C., Keliner, S. et al: The MDR1 modulator dexniguldipine (DNIG) has antineoplastic activity in metastatic renal cell cancer. Proc Am Soc Clin Oncol, 13: 158, 1994
25. Kish, J. A., Ensley, J. F. and Al-Sarraf, M.: Phase II evaluation of 4′deoxydoxorubicin in advanced renal cell carcinoma. Am J Clin Oncol, 13: 17, 1990
26. Venner, P., Eisenhauer, E. A., Wierzbicki, R. et al: Phase II study of 2′-deoxycoformycin in patients with renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs, 9: 273, 1991
27. Scheithauer, W., Kuehrer, I., Kutzmits, R. et al: Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma. J Biol Regul Homeost Agents, 1: 81, 1987
28. Witte, R. S., Walsh, C., Fisher, H. et al: Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. An ECOG pilot study. Invest New Drugs, 10: 49, 1992
29. Motzer, R. J., Scher, H., Bajorin, D. et al: Phase II trial of didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs, 8: 391, 1990
30. Bruntsch, U., Heinrich, B., Kay, S. B. et al: Docetaxel (taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer, 30A: 1064, 1994
31. Marshall, M. E., Wolf, M. K., Crawford, E. D. et al: Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study. Invest New Drugs, 11: 207, 1993
32. Chang, A. Y., Tu, Z. N., Bryan, G. T. et al: Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885. Invest New Drugs, 12(2): 151, 1994
33. Dreicer, R., Propert, K. J., Kuzel, T. et al: A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol, 20(3): 251, 1997
34. Ahlgren, J. D., Lokich, J., Auerbach, M. et al: Protracted infustional 5FU: a well-tolerated regimen in metastatic renal carcinoma. A Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol, 12: 244, 1993
35. Kish, J. A., Wolf, M., Crawford, E. D. et al: Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer, 74: 916, 1994
36. Hrushesky, W. J., von Roemeling, R., Lanning, R. M. et al: Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol, 8: 1504, 1990
37. Damascelli, B., Marchiano, A., Spreafico, C. et al: Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer, 66: 237, 1990
38. Merrouche, Y., Negrier, S., Lanier, F. et al: Phase II study of continuous circadian infusion FUDR in metastatic renal cell cancer (RCC). Eur J Cancer, 27: S102, 1991
39. Dexeus, F. H., Logothetis, C. J., Sella, A. et al: Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol, 146: 709, 1991
40. Budd, G. T., Murthy, S., Klein, E. et al: Time-modified infusion of floxuridine in metastatic renal cell carcinoma. Proc Am Assoc Cancer Res, 33: 220, 1992
41. Conroy, T., Geoffrois, L., Guillemin, F. et al: Simplified chrono-modulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer, 72: 2190, 1993
42. Aveta, P., Terrone, C., Neira, D. et al: Chemotherapy with FUDR in the management of metastatic renal cell carcinoma. Ann Urol (Paris), 31: 159, 1997
43. Wilkinson, M. J., Frye, J. W., Small, E. J. et al: A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer, 71: 3601, 1993
44. Baiocchi, C., Landonio, G., Cacioppo, C. et al: Continuous non chronomodulated infusion of floxuridine in metastatic renal cell carcinoma (MRCC); report of 17 cases. Tumori, 82: 225, 1996
45. Lasset, C., Merrouche, Y., Negrier, S. et al: Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemother Pharmacol, 32: 329, 1993
46. Esteban, E., Buesa, J. M., Cueva, J. et al: Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma. Eur J Cancer, 29A: 1354, 1993
47. Mertens, W. C., Eisenhauer, E. A., Moore, M. et al: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol, 4: 331, 1993
48. de Mulder, P. H., Weissbach, L., Jakse, G. et al: J Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol, 37: 491, 1996
49. Escudier, B., Fizazi, K., Rolland, F. et al: Phase II study of irinotecan (CPT 11) in pretreated or not pretreated patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 16: 33a, 1997
50. Law, T. M., Mencel, P. and Motzer, R. J.: Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs, 12: 323, 1994
51. Schomburg, A., Menzel, T., Hadam, M. et al: Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma. Mol Biother, 4: 58, 1992
52. Stephens, R. L., Goodman, P., Crawford, E. D. et al: Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504). Invest New Drugs, suppl., 8: S69, 1990
53. Long, H. J., Hauge, M. D., Therneau, T. M. et al: Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs, 9: 261, 1991
54. Flanigan, R. C., Saiers, J. H., Wolf, M. et al: Phase II evaluation of merbarone in renal cell carcinoma. Invest New Drugs, 12: 147, 1994
55. Canobbio, L., Boccardo, F., Guarneri, D. et al: Phase II study of navelbine in advanced renal cell carcinoma. Eur J Cancer, 27: 804, 1991
56. Wilding, G., Kirkwood, J., Clamon, G. et al: Phase II trial of navelbine in metastatic renal cancer. Proc Am Soc Clin Oncol, 12: 253, 1993
57. Einzig, A. I., Gorowski, E., Sasloff, J. et al: Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest, 9: 133, 1991
58. Allen, A., Wolf, M., Crawford, E. D. et al: Phase II evaluationof piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study. Invest New Drugs, 10: 129, 1992
59. Shevrin, D., Wade, J., Mullane, M. et al: Phase II study of piroxantrone in advanced renal cell cancer (RCC): an Illinois Cancer Center study. Proc Am Soc Clin Oncol, 12: 240, 1993
60. Vogelzang, N. J., Mani, S., Schilsky, R. L. et al: Phase II and pharmacokinetic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res, 4: 929, 1998
61. Weinerman, B., Eisenhauer, E., Stewart, D. et al: Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. Ann Oncol, 3: 83, 1992
62. Mahjoubi, M., Kattan, J., Bonnay, M. et al: Phase II trial of LY 186641 in advanced renal cancer. Invest New Drugs, 11: 323, 1993
63. La Rocca, R. V., Stein, C. A., Danesi, R. et al: A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer, 67: 1509, 1991
64. Motzer, R. J., Nanus, D. M., O'Moore, P. et al: Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res, 52: 5775, 1992
65. Shevrin, D. H., Kilton, L. J., Lad, T. E. et al: Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center Study. Invest New Drugs, 12: 345, 1994
66. Law, T. M., Ilson, D. H. and Motzer, R. J.: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs, 12: 143, 1994
67. Witte, R. S., Elson, P., Bryan, G. T. et al: Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial: Invest New Drugs, 10: 51, 1992
68. Fossa, S. D., Droz, J. P., Pavone-Macaluso, M. M. et al: Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer, 28A: 878, 1992
69. Motzer, R. J., Nanus, D. M., Scher, H. I. et al: A phase II trial of suramin in patients with advanced renal cell carcinoma. Proc Am Assoc Cancer Res, 33: 220, 1992.
70. Poorter, R. L., Bakker, P. J. M., Kurth, K. H. et al: Circadian modulated continuous infusion of FUDR in patients with disseminated renal cell cancer (RCC). Eur J Cancer, 29: 116, 1993
71. Raminski, D., Creaven, P. J., Rustum, Y. M. et al: Phase I clinical trial of floxuridine (FUdR) with leucovorin (LV) in patients (PTS) with advanced genitourinary cancer (AGC). Proc Am Soc Clin Oncol, 11: 206, 1992
72. Bjarnason, G. A., Hrushesky, W. J. M., Diasio, R. et al: Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study. Proc Am Soc Clin Oncol, 13: 233, 1994
73. Mani, S., Gordon, G., Vogelzang, N. J. et al: A phase I trial of continuous 5-fluorouracil and weekly gemcitabine: updated results of an active combination for renal cell, hepatocellular and colon carcinoma. Ann Oncol, suppl., 9: 165, 1998
74. Stadler, W. M., Dumas, M., Flickinger, S. et al: Gemcitabine and 5-fluorouracil in metastaic renal carcinoma; a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol, 18: 332a, 1999
75. Berlin, J., King, A. C., Tutsch, K. et al: A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs, 12: 137, 1994
76. Overmoyer, B., Fox, K., Tomaszewski, J. et al: A phase II trial of R-verapamil and infusional vinblastine in advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 12: 251, 1993
77. Motzer, R. J., Lyn, P., Fischer, P. et al: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol, 13: 1958, 1995
78. Mickisch, G. H., Noordzij, M. A., Gaast, V. D. et al: Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol, suppl., 121: R11, 1995
79. Murphy, B. R., Rynard, S. M., Pennington, K. L. et al: A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am J Clin Oncol, 17: 10, 1994
80. Warner, E., Tobe, S. W., Andrulis, I. L. et al: Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Amer J Clin Oncol, 18: 251, 1995
81. Samuels, B. L., Hollis, D. R., Rosner, G. L. et al: Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a Cancer and Leukemia Group B study. Clin Cancer Res, 3: 1977, 1997
82. Schwartsmann, G., Medina de Cunha, F., Silveira, L. A. et al: Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol, 2: 443, 1991
83. Lemon, S., Meadows, B., Fojo, A. et al: A phase I study of infusional vinblastine with the p-glycoprotein antagonist PSC 833 in patients with metastatic cancer. Proc Am Soc Clin Oncol, 14: 479, 1995
84. Agarwala, S. S., Bahnson, R. R., Wilson, J. W. et al: Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol, 18: 211, 1995
85. Vallis, K., Philip, P., Rockett, H. et al: Multidrug resistance reversal with toremifine in renal cell cancer. Proc Am Soc Clin Oncol, 69: 23, 1994
86. Gehling, U., Weimar, C., Schuler, U. et al: Phase I/II study of dexniguldipine and doxorubicin in advanced renal cell carcinoma. FASEB J, 9: A96, 1995
87. Tueni, E., Majois, F., Blijham, G. et al: Phase IB study of S9788 a novel multidrug resistance revertant in combination with adriamycin in patients with colorectal or renal cell cancers. Proc Am Soc Clin Oncol, 14: 182, 1995
88. Stahl, M., Schmoll, E., Becker, H. et al: Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin Oncol, 18: 33, 1991
89. Stahl, M., Wilke, H., Schmoll, H. J. et al: A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol, 3: 167, 1992
90. Schomburg, A., Kirchner, H., Fenner, M. et al: Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer, 29A: 737, 1993
91. Gershanovich, M. M., Moiseyenko, V. M., Vorobjev, A. V. et al: High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol, 39: 547, 1997
92. Inhorn, L., Williams, S. D., Nattam, S. et al: High-dose cimetidine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group study. Am J Clin Oncol, 15: 157, 1992
93. Rini, B. I., Stadler, W. M., Spielberger, R. T. et al: Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: a phase II trial: Cancer, 82: 1352, 1998
94. Redman, B. G., Abubar, Y., Chou, T. et al: Phase II trial of recombinant interleukin-1beta in patients with metastatic renal cell carcinoma. J Immunother Emphasis Tumor-Immunol, 16: 211, 1994
95. Stadler, W. M., Rybak, M. E. and Vogelzang, N. J.: A phase II study of subcutaneous recombinant interleukin-4 in metastatic renal cell carcinoma. Cancer, 76: 1629, 1995
96. Whitehead, R. P., Blumenstein, B., Flanigan, R. C. et al: Phase II trial of recombinant human interleukin-4 in patients with disseminated renal cell adenocarcinoma: a Southwest Oncology Group study. Proc Am Soc Clin Oncol, 15: 259, 1996
97. Stouthard, J. M., Goey, H., de Vries, E. G. et al: Recombinant human interleukin-6 in metastatic renal cell cancer: a phase II trial. Br J Cancer, 73: 789, 1996
98. Schuler, M., Bruntsch, U., Spath-Schwalbe, E. et al: Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. Eur J Cancer, 34: 754, 1998
99. Atkins, M. B., Robertson, M. J., Gordon, M. et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res, 3: 409, 1997
100. Motzer, R. J., Rakhit, A., Schwartz, L. H. et al: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res, 4:1183, 1998
101. Pruthi, R. K., Kvols, L. K., Ewel, C. H. et al: Phase II study of high and low dose lanreotide in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 15: A694, 1996
102. Picus, J., Walker, P. R., Webb, C. et al: A phase II study of levamisole in the treatment of advanced renal cell cancer: A Hoosier Oncology Group study. Proc Am Soc Clin Oncol, 15: 260, 1996
103. Pawinski, A., Oosterom, A. T., de Wit, R. et al: An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Eur J Cancer, 33: 496, 1997
104. de Wit, R., Pawinsky, A., Stoter, G. et al: EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur J Cancer, 33: 493, 1997
105. Mertens, W. C., Chin-Yee, I. and Rudzitis, L.: Oral ranitidine in advanced renal carcinoma: a phase II trial with evaluation of peripheral blood lymphocyte subsets. Proc Am Soc Clin Oncol, 15: 355, 1996
106. Bergh, J., Bjork, P., Westlin, J. E. et al: Expression of an estramustine-binding associated protein in human lung cancer cell lines. Cancer Res, 48: 4615, 1988
107. Berg, W. J., Bukowski, R., Thompson, J. A. et al: A randomized phase II trial of recombinant human interleukin-12 (IL-12) versus interferon alpha-2a (IFN) in advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 17: 318, 1998
108. Wigginton, J. M., Komschlies, K. L., Back, T. C. et al: Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst, 88: 38, 1996
109. Minasian, L. M., Motzer, R. J., Gluck, L. et al: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol, 11: 1368, 1993
110. Fossa, S. D., Martinelli, G., Otto, U. et al: Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol, 3: 301, 1992
111. Neidhart, J. A., Anderson, S. A., Harris, J. E. et al: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol, 9: 832, 1991
112. Krown, S. E.: Interferon treatment of renal cell carcinoma: Current status and future prospects. Cancer, 59: 647, 1987
113. Steineck, G., Strander, H., Carbin, B. E. et al: Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial: Acta Oncologica, 29: 155, 1990
114. Kriegmair, M., Oberneder, R. and Hofstetter, A.: Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology, 45: 758, 1995
115. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial: Lancet, 353: 14, 1999
116. Pyrhönen, S., Salminen, E., Ruutu, M. et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 17: 2859, 1999
117. Law, M. T., Motzer, R. J., Mazumdar, M. et al: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76: 824, 1995
118. McCabe, M. S., Stablein, D. and Hawkins, M. J.: The modified Group C experience-phase III randomized trials of IL-2 versus IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol, 10: 213, 1991
119. Fyfe, G., Fisher, R. I., Rosenberg, S. A. et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 13: 688, 1995
120. Sleijfer, D. T., Janssen, R. A., Buter, J. et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol, 10: 1119, 1992
121. Yang, J. C., Topalian, S. L., Parkinson, D. et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol, 12: 1572, 1994
122. Yang, J. C. and Rosenberg, S. A.: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am, 3: S79, 1997
123. Atkins, M. B. and Dutcher, J. P.: Renal-cell carcinoma. N Engl J Med, 336: 809, 1997
124. Vogelzang, N. J., Lipton, A. and Figlin, R. A.: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol, 11: 1809, 1993
125. Atkins, M. B., Sparano, J., Fisher, R. I. et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol, 11: 661, 1993
126. Kirchner, H., Buer, J., Probst-Kepper, M. et al: Risk and long-term outcome in metastatic renal cell carcinoma patients receiving SC interleukin-2, SC interferon-alfa2a and IV 5-fluoruracil. Proc Am Soc Clin Oncol, 17: 310, 1998
127. Hofmockel, G., Langer, W., Theiss, M. et al: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol, 156: 18, 1996
128. Ellerhorst, J. A., Sella, A., Amato, R. J. et al: Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 80: 2128, 1997
129. Joffe, J. K., Banks, R. E., Forbes, M. A. et al: Phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma. Clinical data and laboratory evidence of protease action. Br J Urol, 77: 638, 1996
130. Dutcher, J., Atkins, M., Fisher, R. et al: Il-2-based therapy in metastatic renal cell cancer: Cytokine Working Group experience. Proc Am Soc Clin Oncol, 16: 327, 1997
131. Gitlitz, B. J., Dolan, N., Pierce, W. et al: Fluoropyrimidines plus interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma: the UCLA Kidney Cancer Program. Proc Am Soc Clin Oncol, 15: 248, 1996
132. Olencki, T., Bukowski, R. M., Budd, G. T. et al: Phase I/II trial of simultaneously administered rIL-2/rHuIFN and 5-FU in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 15: 263, 1996
133. Tourani, J. M., Pfister, C., Berdah, J. F. et al: Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol, 16: 2505, 1998
134. Ravaud, A., Audhuy, B., Gomez, F. et al: Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase trial: Groupe Francois d'Immunotherapie. J Clin Oncol, 16: 2728, 1998
135. Hanninen, E. J., Kirchner, H. and Atzpodien, J.: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol, 155: 19, 1996
136. Negrier, S., Escudier, B., Doullard, J. Y. et al: Randomized study of interleukin-2 and interferon with our without 5-FU (FUCY study) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 16: 326, 1997
137. Motzer, R. J., Schwartz, L., Law, T. M. et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol, 13: 1950, 1995
138. Paule, B., Bonhomme-Faivre, L., Rudant, E. et al: Interferon alfa-2a plus tretinoin in patients with metastatic renal cell carcinoma: a pilot study. Am J Health Syst Pharm, 54: 190, 1997
139. Atzpodien, J., Buer, J., Probst, M. et al: Clinical and pre-clinical role of 13-cis-retinoic acid in renal cell carcinoma: Hannover experience. Proc Am Soc Clin Oncol, 15: 247, 1996
140. Motzer, R. J., Murphy, B. A., Mazumdar, M. et al: Randomized phase III trial of interferon alfa-2a (IFN) versus IFN plus 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 18: 330a, 1999
141. Sagaster, P., Micksche, M., Flamm, J. et al: Randomised study using IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol, 6: 999, 1995
142. de Mulder, P., Oosterhof, G., Bouffioux, C. et al: EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Brit J Cancer, 71: 371, 1995
143. Figlin, R., Thompson, J., Roudet, C. et al: Multi-center randomized placebo controlled phase II/III trial of CD8(+) tumor infiltrating lymphocyte therapy (CD8(+) TIL)/recombinant interleukin-2 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 17: 318A, 1998
144. McCaffrey, J. A. and Motzer, R. J.: What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol, 23: xix, 1996
145. Couillard, D. R. and deVere White, R. W.: Surgery of renal cell carcinoma. Urol Clin N Am, 20: 263, 1993
146. Kavolius, J. P., Mastorakos, D. P., Pavlovich, C. et al: Resection of metastatic renal cell carcinoma. J Clin Oncol, 16: 2261, 1998
147. Robertson, C. N., Linehan, W. M., Pass, H. I. et al: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol, 144: 614, 1990
148. Rackley, R. R., Klein, E. A. and Novick, A. D.: Morbidity and mortality of primary adjuvant nephrectomy in immunotherapy for renal cell carcinoma. J Urol, 145: 422A, abstract 839, 1991
149. Bennett, R. T., Lerner, S. E., Taub, H. C. et al: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol, 154: 32, 1995
150. Fleischmann, J. D. and Kim, B.: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol, 145: 938, 1991
151. Rackley, R., Novick, A., Klein, E. et al: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol, 152: 1399, 1994
152. Walther, M. M., Yang, J. C., Pass, H. I. et al: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol, 158: 1675, 1997
153. Franklin, J. R., Figlin, R., Rauch, J. et al: Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol, 14: 230, 1996
154. Fallick, M. L., McDermott, D. F., LaRock, D. et al: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol, 158: 1691, 1997
155. Sella, A., Swanson, D. A., Ro, J. Y. et al: Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol, 149: 19, 1993
156. Tanguay, S., Swanson, D. A. and Putman, J. B., Jr.: Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J Urol, 156: 1586, 1996
157. Elson, P. J., Witte, R. S. and Trump, D. L.: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res, 48: 7310, 1988
158. De Forges, A., Rey, A., Klink, M. et al: Prognostic factors of adult metastatic renal cell carcinoma: a multivariate analysis. Semin Surg Oncol, 4: 149, 1988
159. Palmer, P. A., Vinke, J., Philip, T. et al: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol, 3: 475, 1992
160. Jones, M., Philip, T., Palmer, P. et al: The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother, 8: 275, 1993
161. Fossa, S. D., Kramar, A. and Droz, J. P.: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer, 30A: 1310, 1994
162. Motzer, R. J., Mazumdar, M., Bacik, J. et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17: 2530, 1999.
163. Sandock, D. S., Seftel, A. D. and Resnick, M. I.: A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol, 154: 28, 1995
164. Rabinovitch, R. A., Zelefsky, M. J., Gaynor, J. J. et al: Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol, 12: 206, 1994
165. Levy, D. A., Slaton, J. W., Swanson, D. A. et al: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol, 159: 1163, 1998
166. Kjaer, M., Frederiksen, P. L. and Engelholm, S. A.: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Physiol, 13: 665, 1987
167. Finney, R.: The value of radiotherapy in the treatment of hypernephroma - a clinical trial: Br J Urol, 45: 258, 1973
168. Trump, D. L., Elson, P., Propert, K. et al: Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma. Proc Am Soc Clin Oncol, 15: 253, 1996
169. Porzsolt, F.: Adjuvant therapy of renal cell cancer with interferon alfa-2a. Proc Am Soc Clin Oncol, 11: 202, 1992
170. Pizzocaro, G., Piva, L., Costa, A. et al: Adjuvant interferon to radical nephrectomy in Robson's stage II and III renal cell cancer, a multicenter randomized study with some biological evaluations. Proc Am Soc Clin Oncol, 16: 318A, 1997
171. Gunnett, K., Motzer, R., Amato, R. et al: Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 18: 340a, 1999
172. Divgi, C. R., Bander, N. H., Scott, A. M. et al: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res, 4: 2729, 1998
173. Hinkel, A., Gitlitz, B., Mulders, P. et al: Dendritic cell therapy for metastatic renal cell carcinoma: a translational phase I clinical trial. Proc Am Soc Clin Oncol, 17: 432, 1998
174. Jaffee, E. M., Marshall, F., Weber, C. et al: Bioactivity of a human GM-CSF tumor vaccine for the treatment of metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 15: 237, 1996
175. O'Byrne, K. J., Propper, D., Braybooke, J. et al: Razoxane: a phase II trial in renal cell cancer evaluating anti-angiogenic activity. Proc Am Soc Clin Oncol, 16: 325a, 1997
176. Stadler, W. M., Shapiro, C. L., Sosmann, J. et al: A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 17: 310, 1998